Vanta Bioscience Ltd IPO Review (Date, Price, DRHP)

Vanta Bioscience Ltd IPO Review

Vanta Bioscience Ltd (VBL) is a preclinical contract research company whhich offers safety assessment services for clientele from Pharmaceutical, Medical Devices, Nutraceuticals, Feed Additive, Biotech, Agrochemicals, Cosmetics, and Chemical industries. Its headquartered in the USA. They are coming up with their IPO in the BSE SME. This post will do the Vanta Bioscience Ltd IPO review and will check the investment pros and cons for the blog readers.

About Vanta Bioscience Ltd IPO :

  • IPO opens on – September 25, 2017
  • IPO closes on – September 27, 2017
  • Face value – Rs. 10 per equity share
  • Issue price – Rs. 50 Per Equity Share.
  • Issue type – Fixed Price Issue IPO.
  • Minimum lot – 3000 shares.
  • Minimum order quantity –  3000 Shares.
  • Issue size – 1,512,000 Equity Shares of Rs 10 up to Rs 7.56 Cr.
  • Listing exchange – BSE SME Exchange.
  • DRHP – Click here to read from SEBI website.

Objectives of the issue :

  • Augmenting additional working capital requirements.
  • General Corporate Purposes.

About The Company-

  • Vanta Bioscience based in Des Moines, Iowa with additional offices in Brussels, Belgium and West Des Moines, Iowa. It has a toxicology research facility in Chennai, India.
  • The Indian pharmaceuticals market is the third largest in terms of volume and thirteenth largest in terms of value.
  • Their services include toxicology, batch release tests, biocompatibility studies, chemical safety, and diet formulation.
  • One of the major services of VBL is conducting variety of in vitro (cell, tissue, and organisms) and in vivo (animal) toxicology studies for its diverse clients as per various regulatory requirements from across the world.
  • They also provides risk assessment services for evaluating the safety of the Active Pharmaceutical Ingredients (API), excipients, extractable and leachable including pharmaceutical impurities resulting due to manufacturing process or due to degradation of the product.
  • The company also provides expert services for determination of health-based exposure limits permitted daily exposure (PDE) or allowable daily exposure (ADE) including occupational exposure limits (OEL) for pharmaceutical manufacturers.

Vanta Bioscience Ltd

Join Our Team For Rocket Calls

Promoters of the company :

  • Mohan Krishna Mulakala.
  • Dopesh Raja Mulakala.
  • Dr Vyasmurti Madhavrao Shingatgeri
  • Dr. Soumya Simhadri.
  • Shravan Chintapatla.
  • Karishma Mulakala.
  • Sajan Kiran Mulakala.
  • Pradeep Chowdary.
  • Dr. Chandrasekhar Rao Simhadri.

Name of the top shareholders :

  • Mohan Krishna Mulakala.
  • Sujana Sheela Mulakala.
  • Dopesh Raja Mulakala.
  • B. Heala Rao.
  • B. V. Rao.
  • D. Srinivas.
  • Triveni Mulakala.
  • T. Sulochana Rao.
  • T. Jagadish Kumar rao.
  • B. Prem Kumari.
  • D Kishore.
  • D Parameswari.
  • Dinkar Mulakala.
  • Karishma Mulakala.
  • Sajan Kiran Mulakala.
  • Sireesha Rao Mavoori.
  • T Appa Rao.
  • Umamaheswari Dontamsetti.

Company Financials:

Vanta Bioscience Ltd IPO

Vanta Bioscience Ltd IPO1

Vanta Bioscience Ltd IPO Review: In this month some big names are going to be listed in the exchange. Two of them are from the insurance sector: ICICI Lombard and SBI Life Insurance. We advise safe investors to invest on these mega issues and avoid unknown companies in SME exchanges. Hence this Vanta Bioscience Ltd IPO review puts a RISKY tag on this issue.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.